Chronic myelomonocytic leukaemia

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search

Haematolymphoid Tumours (5th ed.)

editHAEM5 Conversion Notes
This page was converted to the new template on 2023-12-07. The original page can be found at HAEM4:Chronic Myelomonocytic Leukemia (CMML).

(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use HUGO-approved gene names and symbols (italicized when appropriate), HGVS-based nomenclature for variants, as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see Author_Instructions and FAQs as well as contact your Associate Editor or Technical Support)

Primary Author(s)*

Linsheng Zhang, MD, PhD

Cancer Category / Type

Myeloid Neoplasm

Cancer Sub-Classification / Subtype

Myelodysplastic/Myeloproliferative Neoplasm (MDS/MPN)

Definition / Description of Disease

Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative neoplasm (MDS/MPN) with persistent monocytosis (absolute monocyte count ≥1 x 109/L and ≥10% of leukocytes are monocytes). When myelodysplasia is absent or minimal, clonal evidence(s) of acquired cytogenetic or molecular genetic change(s) in hematopoietic cells, or unexplained monocytosis persisted for ≥3 months supports the diagnosis of CMML.

Before a diagnosis of CMML can be rendered, other well-defined myeloid neoplasms that sometimes present with monocytosis, such as BCR-ABL1-positive chronic myeloid leukemia (especially with p190 fusion) and myeloid/lymphoid neoplasms with rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2 must be ruled out. Dysplastic features are usually seen in at least one myeloid lineage. By definition, the blast percentage must be <20%.

CMML can be subdivided into three categories based on the percentage of blasts and promonocytes (considered blast equivalent) in the peripheral blood and bone marrow[1]:

CMML-0: < 2% blasts in the blood and < 5% in the bone marrow; and no Auer rods.

CMML-1: 2-4% blasts in the blood or 5-9% in the bone marrow; and no Auer rods.

CMML-2: 5-19% blasts in the blood, 10-19% in the bone marrow or Auer rods are present.

Synonyms / Terminology

Put your text here (Instructions: Include currently used terms and major historical ones, adding “(historical)” after the latter.)

Epidemiology / Prevalence

Historically CMML was classified as a subtype of MDS. The exact incidence of CMML is difficult to calculate based on the published data. Recent studies reported approximate incidence of 0.4 cases per 100,000 population[2]. The median patient age at diagnosis is 65-75 years, with a slight male dominance (male-to female ratio of 1.5-3:1)[3][4][5].

Clinical Features

Put your text here and fill in the table (Instruction: Can include references in the table)

Signs and Symptoms EXAMPLE Asymptomatic (incidental finding on complete blood counts)

EXAMPLE B-symptoms (weight loss, fever, night sweats)

EXAMPLE Fatigue

EXAMPLE Lymphadenopathy (uncommon)

Laboratory Findings EXAMPLE Cytopenias

EXAMPLE Lymphocytosis (low level)


editv4:Clinical Features
The content below was from the old template. Please incorporate above.

The clinical features are variable and significantly related to blood cell counts[3][1]. Some clinical presentations may be different in dysplastic (WBC count < 13 x 109/L) and proliferative (WBC count ≥ 13 x 109/L) subgroups[4]. In patients with increased white blood cell (WBC) count (~50% of all cases), constitutional symptoms (e.g. weight loss, fever, and night sweats) are common. In cases with cytopenia(s), similar to MDS, clinical presentations are usually related to insufficient blood cells (anemia, leukopenia and/or thrombocytopenia, e.g. fatigue, infection, and bleeding tendency)[6]. Hepatosplenomegaly can be present in both subgroups, but are frequently related to leukocytosis. Rare cases with life-threatening hyperleukocytosis have been reported.

Sites of Involvement

Blood and bone marrow (always involved).

The common sites of extramedullary infiltrate include spleen, liver, skin and lymph nodes[3][1][7], involvement of other organs, although less common, have also been reported.

Morphologic Features

Blood:

  • Monocytosis ≥ 1 x 109/L and monocytes account for ≥ 10% of the leukocytes.

Monocyte morphology ranges from normal to atypical: unusual nuclear segmentation or chromatin patterns, and abnormal cytoplasmic granulation.

  • Blasts and promonocytes together must be <20% of the leukocytes.
  • Variable changes in other blood cells are usually present.
    • WBC count: increased, normal to slightly decreased, with neutropenia
    • Granulocytes frequently left-shifted with occasional immature forms (promyelocytes, myelocytes and metamyelocytes, usually < 10% of the leukocytes)
    • Dysplastic features in neutrophils (more frequently related to leukopenia): hyposegmented or abnormally segmented nuclei, abnormal cytoplasmic granulation
    • Eosinophilia
    • Mild anemia, often normocytic or macrocytic, nucleated red blood cells may be seen
    • Thrombocytopenia with atypical, large platelets.
Blood smear, 200X (Wright stain)

Bone marrow:

  • Usually hypercellular (>75% of cases) but rarely can be hypocellular.
  • The myeloid to erythroid ratio is generally increased with dysplastic granulocytic hyperplasia.
    • Monocytes can be difficult to recognize in the bone marrow, especially when many dysplatic granulocytes are present.
    • Cytochemical studies (Alpha-naphthyl butyrate esterase or alpha-naphthyl acetate esterase with fluoride inhibition staining of blood and bone marrow aspirate smears can be useful to facilitate better recognition of the monocytic component.
  • Mild dyserythropoiesis (e.g. megaloblastoid changes, abnormal nuclear features and ring sideroblasts) in some cases.
  • Dysmegakaryopoiesis are present in many cases.
  • Mild to moderate increase in the number of reticulin fibers seen in nearly 30% of cases[8].
  • Nodules composed of mature plasmacytoid dendritic cells in the bone marrow biopsy have been reported in 20% of cases[9].
Bone marrow aspirate smear, 600X (Wright stain)

Spleen and lymph node:

  • Red pulp infiltrate in spleen.
  • Lymph node infiltrate less common
  • Involvement by a diffuse infiltration of plasmacytoid dendritic cells can be seen in lymph node and less commonly in spleen

Immunophenotype

The neoplastic monocytic cells frequently show some aberrant immunophenotype. Recognizing monoblasts by immunophenotype can be very challenging.

Finding Marker
Positive (universal) CD13, CD33
Positive (variable, can be aberrantly decreased) CD11c, CD13, CD14, CD15, CD16, CD36, CD64, CD64, CD68, HLA-DR
Positive (aberrant, variable) CD56, CD2. Increased CD34+ blasts suggest disease progression
Negative (universal) CD3, CD5, CD20, CD79a (T-cell and B-cell markers)
Negative (subset) CD14, CD56

Chromosomal Rearrangements (Gene Fusions)

Put your text here and fill in the table

Chromosomal Rearrangement Genes in Fusion (5’ or 3’ Segments) Pathogenic Derivative Prevalence Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE t(9;22)(q34;q11.2) EXAMPLE 3'ABL1 / 5'BCR EXAMPLE der(22) EXAMPLE 20% (COSMIC)

EXAMPLE 30% (add reference)

Yes No Yes EXAMPLE

The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).


editv4:Chromosomal Rearrangements (Gene Fusions)
The content below was from the old template. Please incorporate above.

No chromosome rearrangements specifically associated with CMML.

By definition, the presence of BCR-ABL11 or rearrangements involving PDGFRA, PDGFRB or FGFR1 and PCM1-JAK2 defines categories other than CMML.


editv4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).
Please incorporate this section into the relevant tables found in:
  • Chromosomal Rearrangements (Gene Fusions)
  • Individual Region Genomic Gain/Loss/LOH
  • Characteristic Chromosomal Patterns
  • Gene Mutations (SNV/INDEL)

Presence of one or more mutations, especially concurrent mutations in TET2 and SRSF2 is very helpful for a definitive diagnosis.

Survival times range from 1 month to > 100 months; the median survival time in most series is 20-40 months[10][11][12][13].

15- 30% of cases progress to acute myeloid leukemia (AML), classified as AML with myelodysplasia-related changes (MRC).

Important factors predicting progression and survival time[12]:

  • Percentage of blasts in blood and bone marrow is the most important factor determining survival
  • Karyotype, ASXL1 mutation[14]
  • Leukocytosis

Other predictive factors for disease progression:

  • Lactate dehydrogenase (LDH) level
  • Splenomegaly
  • Anemia, thrombocytopenia and lymphocytosis (>2.5 x 109/L)

Somatic ASXL1 mutation has also been incorporated in a clinical prognostic scoring system[14].

Individual Region Genomic Gain / Loss / LOH

Put your text here and fill in the table (Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.)

Chr # Gain / Loss / Amp / LOH Minimal Region Genomic Coordinates [Genome Build] Minimal Region Cytoband Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE

7

EXAMPLE Loss EXAMPLE

chr7:1- 159,335,973 [hg38]

EXAMPLE

chr7

Yes Yes No EXAMPLE

Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference).  Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference).

EXAMPLE

8

EXAMPLE Gain EXAMPLE

chr8:1-145,138,636 [hg38]

EXAMPLE

chr8

No No No EXAMPLE

Common recurrent secondary finding for t(8;21) (add reference).

editv4:Genomic Gain/Loss/LOH
The content below was from the old template. Please incorporate above.

Clonal cytogenetic abnormalities are found in 20-40% of CMML cases, but there are no specific abnormalities[15].

Chromosomal Abnormality Prevalence
Trisomy 8 up to 10%
del(20q) up to 10%
-Y 4%
-7 or del(7q) 1.5%
Complex 3%

Characteristic Chromosomal Patterns

Put your text here (EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis)

Chromosomal Pattern Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE

Co-deletion of 1p and 18q

Yes No No EXAMPLE:

See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).

editv4:Characteristic Chromosomal Aberrations / Patterns
The content below was from the old template. Please incorporate above.

No characteristic chromosome aberrations identified in association with CMML.

Gene Mutations (SNV / INDEL)

Put your text here and fill in the table (Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.)

Gene; Genetic Alteration Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other) Prevalence (COSMIC / TCGA / Other) Concomitant Mutations Mutually Exclusive Mutations Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE: TP53; Variable LOF mutations

EXAMPLE:

EGFR; Exon 20 mutations

EXAMPLE: BRAF; Activating mutations

EXAMPLE: TSG EXAMPLE: 20% (COSMIC)

EXAMPLE: 30% (add Reference)

EXAMPLE: IDH1 R123H EXAMPLE: EGFR amplification EXAMPLE:  Excludes hairy cell leukemia (HCL) (add reference).


Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.


editv4:Gene Mutations (SNV/INDEL)
The content below was from the old template. Please incorporate above.

Over 90% of CMML patients studied exhibited one or more mutations[1]. Concurrent mutations in TET2 and SRSF2 appear to be highly specific for this entity[16][17]. Mutations in certain pathways correlated with clinical classification (dysplastic vs. proliferative)[18].

Gene Mutation Prevalence[1][16]
TET2 50-60%
SRSF2 40-50%
ASXL1 35-40%
RUNX1 15-25%, usually secondary[19]
NRAS p.G12 most common 11%
CBL 10%
JAK2 V617F 10%
NOTCH 10%

Other Mutations

Type Gene/Region/Other
Mutation prevalence not well studied in PTPN11, DNMT3A, IDH2, IDH1, SF3B1,U2AF35, ZRSR2, UTX, EZH2,

KRAS, CBL, CSF3R, SETBP1

Uncommon Mutations in NPM1, CEBPA, FLT3-ITD, TP53

The clonal evolution and secondary subclonal hierarchy may be correlated with clinical phenotypes or outcomes[18].

Epigenomic Alterations

The genome-wide methylation profiles showed limited applicability in a diagnostic setting[20][21].

The methylation level of individual selected gene promoters have been correlated with overall survival (OS) and progression free survival (PFS)[21]:

  • CDH1, ETS1, DAXX, FADD, DAPP1, AATK, CYFIP, TP53, BP2, and AIM2, which were hypermethylated in CMML samples.
  • BCL2 hypomethylation is predictive of poorer OS and PFS.

Genes and Main Pathways Involved

Put your text here and fill in the table (Instructions: Can include references in the table.)

Gene; Genetic Alteration Pathway Pathophysiologic Outcome
EXAMPLE: BRAF and MAP2K1; Activating mutations EXAMPLE: MAPK signaling EXAMPLE: Increased cell growth and proliferation
EXAMPLE: CDKN2A; Inactivating mutations EXAMPLE: Cell cycle regulation EXAMPLE: Unregulated cell division
EXAMPLE:  KMT2C and ARID1A; Inactivating mutations EXAMPLE:  Histone modification, chromatin remodeling EXAMPLE:  Abnormal gene expression program

Genetic Diagnostic Testing Methods

  • Blood cell counts and smear review.
  • Bone marrow aspirate and core biopsy with flow cytometric immunophenotyping and immunohistochemical stains.
  • Molecular genetic studies are essential to provide clonal evidence for a diagnosis of a myeloid neoplasm, and rule out other well defined entities.
  • There are no diagnostic molecular/genetic abnormalities specific for CMML.

Familial Forms

Familial form of CMML has not been reported.

A patient with CMML secondary to familial platelet disorder with germline RUNX1 mutation (classified as myeloid neoplasm with germline RUNX1 mutation) was reported after acquired CBL mutation and 11q-acquired uniparental disomy (11q-aUPD)[22].

Additional Information

Acute myeloid leukemia (AML) with monocytic differentiation frequently have increased circulating mature monocytes (more mature forms than in the bone marrow), the final diagnosis of CML should never be rendered without an evaluation of BM to rule out acute myeloid leukemia. Rarely, CMML can be "marrow-predominant", with monocytes largely confined to the BM without showing absolute monocytosis[23].

Links

Put your text placeholder here (or anywhere appropriate on the page) and use the "Link" icon at the top of the page (Instructions: Once you have a text placeholder entered to which you want to add a link, highlight that text, select the "Link" icon at the top of the page, and search the name of the internal page to which you want to link this text, or enter an external internet address including the "http://www." portion.)

References

(use the "Cite" icon at the top of the page) (Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference.)

  1. ↑ 1.0 1.1 1.2 1.3 1.4 Arber DA, et al., (2017). Introduction and overview of the classification of myeloid neoplasms, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Editors. IARC Press: Lyon, France, p82-86.
  2. ↑ Dinmohamed, Avinash G.; et al. (2015). "The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands". Leukemia Research. 39 (2): 177–182. doi:10.1016/j.leukres.2014.11.025.
  3. ↑ 3.0 3.1 3.2 Czader, M and Orazi, A. Chapter 45. Myelodysplastic/Myeloproliferative Neoplasms and Related Diseases. In Orazi A, Foucar K, Knowles DM. eds. Knowles Neoplastic Hematopathology. Riverwoods, IL: Wolters Kluwer Health; 2013:1140-1156.
  4. ↑ 4.0 4.1 Germing, Ulrich; et al. (1998). "Problems in the classification of CMML—dysplastic versus proliferative type". Leukemia Research. 22 (10): 871–878. doi:10.1016/S0145-2126(97)00192-6.
  5. ↑ Onida, Francesco; et al. (2002). "Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients". Blood. 99 (3): 840–849. doi:10.1182/blood.V99.3.840. ISSN 1528-0020.
  6. ↑ Storniolo AM, Moloney WC, Rosenthal DS, Cox C, Bennett JM. Chronic myelomonocytic leukemia. Leukemia. 1990;4(11):766‐770.
  7. ↑ Vitte, Franck; et al. (2012). "Specific Skin Lesions in Chronic Myelomonocytic Leukemia: A Spectrum of Myelomonocytic and Dendritic Cell Proliferations. A Study of 42 Cases". The American Journal of Surgical Pathology. 36 (9): 1302–1316. doi:10.1097/PAS.0b013e31825dd4de. ISSN 0147-5185.
  8. ↑ Ratsimbasoa, Arsène; et al. (2006). "Use of pre-packaged chloroquine for the home management of presumed malaria in Malagasy children". Malaria Journal. 5: 79. doi:10.1186/1475-2875-5-79. ISSN 1475-2875. PMC 1592101. PMID 16972985.
  9. ↑ Orazi, Attilio; et al. (2006). "Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistology". Modern Pathology. 19 (12): 1536–1545. doi:10.1038/modpathol.3800707. ISSN 0893-3952.
  10. ↑ Longuet, Christine; et al. (2008). "The glucagon receptor is required for the adaptive metabolic response to fasting". Cell metabolism. 8 (5): 359–371. doi:10.1016/j.cmet.2008.09.008. ISSN 1550-4131. PMC 2593715. PMID 19046568.
  11. ↑ Nijagal, Amar; et al. (2011). "The maternal immune response inhibits the success of in utero hematopoietic cell transplantation". Chimerism. 2 (2): 55–57. doi:10.4161/chim.2.2.16287. ISSN 1938-1956. PMC 3166485. PMID 21912720.
  12. ↑ 12.0 12.1 U, Germing; et al. (2004). "Risk Assessment in Chronic Myelomonocytic Leukemia (CMML)". PMID 15359628.
  13. ↑ A, Worsley; et al. (1988). "Prognostic Features of Chronic Myelomonocytic Leukaemia: A Modified Bournemouth Score Gives the Best Prediction of Survival". PMID 3422815.
  14. ↑ 14.0 14.1 R, Itzykson; et al. (2013). "Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia". PMID 23690417.
  15. ↑ Such, E.; et al. (2011). "Cytogenetic risk stratification in chronic myelomonocytic leukemia". Haematologica. 96 (3): 375–383. doi:10.3324/haematol.2010.030957. ISSN 0390-6078. PMC 3046268. PMID 21109693.CS1 maint: PMC format (link)
  16. ↑ 16.0 16.1 Ti, Mughal; et al. (2015). "An International MDS/MPN Working Group's Perspective and Recommendations on Molecular Pathogenesis, Diagnosis and Clinical Characterization of Myelodysplastic/Myeloproliferative Neoplasms". doi:10.3324/haematol.2014.114660. PMC 4800699. PMID 26341525.CS1 maint: PMC format (link)
  17. ↑ Gelsi-Boyer, Véronique; et al. (2008). "Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1genes". BMC Cancer. 8 (1). doi:10.1186/1471-2407-8-299. ISSN 1471-2407. PMC 2588460. PMID 18925961.CS1 maint: PMC format (link)
  18. ↑ 18.0 18.1 Patel, B J; et al. (2017). "Genomic determinants of chronic myelomonocytic leukemia". Leukemia. 31 (12): 2815–2823. doi:10.1038/leu.2017.164. ISSN 0887-6924.
  19. ↑ Palomo, Laura; et al. (2020). "Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms". Blood. doi:10.1182/blood.2019004229. ISSN 0006-4971.
  20. ↑ Deininger, Michael W.; et al. (2018). "Molecular Alterations in Chronic Myelomonocytic Leukemia Monocytes: Transcriptional and Methylation Profiling". Blood. 132 (Supplement 1): 3889–3889. doi:10.1182/blood-2018-99-115077. ISSN 0006-4971.
  21. ↑ 21.0 21.1 Palomo, Laura; et al. (2018). "DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features". Epigenetics. 13 (1): 8–18. doi:10.1080/15592294.2017.1405199. ISSN 1559-2294. PMC 5837079. PMID 29160764.CS1 maint: PMC format (link)
  22. ↑ Shiba, Norio; et al. (2012). "CBL mutation in chronic myelomonocytic leukemia secondary to familial platelet disorder with propensity to develop acute myeloid leukemia (FPD/AML)". Blood. 119 (11): 2612–2614. doi:10.1182/blood-2011-02-333435. ISSN 0006-4971.
  23. ↑ A, Orazi; et al. (2008). "The Myelodysplastic/Myeloproliferative Neoplasms: Myeloproliferative Diseases With Dysplastic Features". PMID 18480833.

Notes

*Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome. *Citation of this Page: “Chronic myelomonocytic leukaemia”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated 12/13/2023, https://ccga.io/index.php/HAEM5:Chronic_myelomonocytic_leukaemia.

Retrieved from "https://ccga.io/index.php?title=HAEM5:Chronic_myelomonocytic_leukaemia&oldid=13706"